Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 372

1.

Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.

Kim W.

Clin Mol Hepatol. 2018 Dec 28. doi: 10.3350/cmh.2018.0101. [Epub ahead of print] No abstract available.

2.
3.

Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C.

Eom YW, Baik SK.

Clin Mol Hepatol. 2018 Dec 11. doi: 10.3350/cmh.2018.1011. [Epub ahead of print] No abstract available.

4.

Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients.

Lee YB, Lee JH.

Clin Mol Hepatol. 2018 Dec;24(4):372-373. doi: 10.3350/cmh.2018.0098. Epub 2018 Dec 11. No abstract available.

5.

Rehabilitation for social reintegration in liver transplant patients.

Kim JM.

Clin Mol Hepatol. 2018 Dec;24(4):370-371. doi: 10.3350/cmh.2018.1012. Epub 2018 Dec 10. No abstract available.

6.

Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report.

Kumar R, Hsiang JC, Tan J, Thurairajah PH.

Clin Mol Hepatol. 2018 Dec 4. doi: 10.3350/cmh.2018.0063. [Epub ahead of print] No abstract available.

7.

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.

Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, Schmiegel W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T.

Clin Mol Hepatol. 2018 Nov 19. doi: 10.3350/cmh.2018.0029. [Epub ahead of print]

8.

Radiomics and radiogenomics of primary liver cancers.

Jeong WK, Jamshidi N, Felker ER, Raman SS, Lu DS.

Clin Mol Hepatol. 2018 Nov 16. doi: 10.3350/cmh.2018.1007. [Epub ahead of print]

9.

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.

Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU.

Clin Mol Hepatol. 2018 Nov 13. doi: 10.3350/cmh.2018.0054. [Epub ahead of print]

10.

Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis.

Yokoyama K, Yamauchi R, Shibata K, Fukuda H, Kunimoto H, Takata K, Tanaka T, Inomata S, Morihara D, Takeyama Y, Shakado S, Sakisaka S.

Clin Mol Hepatol. 2018 Nov 9. doi: 10.3350/cmh.2018.0039. [Epub ahead of print]

11.

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B.

Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG.

Clin Mol Hepatol. 2018 Oct 23. doi: 10.3350/cmh.2018.0040. [Epub ahead of print]

12.

Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story.

Obed A, Bashir A, Stern S, Jarrad A.

Clin Mol Hepatol. 2018 Dec;24(4):358-366. doi: 10.3350/cmh.2018.0044. Epub 2018 Oct 24.

13.

Pathologic differential diagnosis of metastatic carcinoma in the liver.

Park JH, Kim JH.

Clin Mol Hepatol. 2018 Oct 5. doi: 10.3350/cmh.2018.0067. [Epub ahead of print]

14.

Fatigue and weakness hinder patient social reintegration after liver transplantation.

Kang SH, Choi Y, Han HS, Yoon YS, Cho JY, Kim S, Kim KH, Hyun IG, Shehta A.

Clin Mol Hepatol. 2018 Dec;24(4):402-408. doi: 10.3350/cmh.2018.0028. Epub 2018 Oct 8.

15.

Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level.

Jeon MY, Kim BK, Kim SU.

Clin Mol Hepatol. 2018 Dec;24(4):367-369. doi: 10.3350/cmh.2018.1008. Epub 2018 Sep 19. No abstract available.

16.

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Yeon JE.

Clin Mol Hepatol. 2018 Sep;24(3):294-296. doi: 10.3350/cmh.2018.1009. Epub 2018 Sep 11. No abstract available.

17.

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

Cho YK.

Clin Mol Hepatol. 2018 Sep;24(3):299-301. doi: 10.3350/cmh.2018.1006. Epub 2018 Sep 7. No abstract available.

18.

Prognostic implications of trunk muscle mass in liver cirrhosis.

Han J, Kim W.

Clin Mol Hepatol. 2018 Sep;24(3):297-298. doi: 10.3350/cmh.2018.0069. Epub 2018 Sep 10. No abstract available.

19.

VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature.

Wong YJ, Chew SY, Hsiang JC, Thurairajah PH, Kumar R, Teo EK, Gokhale RS, Noor IBM, Tan J.

Clin Mol Hepatol. 2018 Sep 6. doi: 10.3350/cmh.2018.0017. [Epub ahead of print] No abstract available.

20.

Biochemical profile in an infant with neonatal hemochromatosis shows evidence of impairment of mitochondrial long-chain fatty acid oxidation.

Bastos KLM, Quaio CR, Lima FR, Araújo IM, Araújo CAT, Piazzon FB, Silva IDCGD, Benevides GN, Tannuri AC, Tannuri U, Azevedo RA, Kim CA.

Clin Mol Hepatol. 2018 Aug 28. doi: 10.3350/cmh.2018.0005. [Epub ahead of print] No abstract available.

Supplemental Content

Loading ...
Support Center